Guidelines from clinical practice offer recommendations of an analysis of mutations in EGFR before the start of therapy of advanced NSCLC (D’Addario et al., 2009; Azzoli et al., 2010; Ettinger et al., 2018). Here, EGFR is linked to non-small cell lung carcinoma.